Get started
Author

Kerri‐Lee Wallom

Observed names: Kerri L Wallom, Kerri L. Wallom, Kerri-Lee Wallom, Kerri‑Lee Wallom
Observed institutions: Goethe University Frankfurt, National Institutes of Health, University of Oxford, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Aligning Science Across Parkinson's, Cardiff University, University of Wales
ORCID: 0000-0002-2842-1275
Observed ORCID: 0000-0002-2842-1275
OpenAlex ID: A5013449164
Heat shock protein–based therapy as a potential candidate for treating the sphingolipidoses
2016 · Thomas Kirkegaard, James Gray, et al. · Science Translational Medicine · 173
Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1
2009 · David Smith, Kerri-Lee Wallom, et al. · Neurobiology of Disease · 146
Relative acidic compartment volume as a lysosomal storage disorder–associated biomarker
2014 · Danielle te Vruchte, Anneliese O. Speak, et al. · Journal of Clinical Investigation · 82
Improved neuroprotection using miglustat, curcumin and ibuprofen as a triple combination therapy in Niemann–Pick disease type C1 mice
2014 · Ian M. Williams, Kerri-Lee Wallom, et al. · Neurobiology of Disease · 79
GM1 ganglioside-independent intoxication by Cholera toxin
2018 · Jakob Cervin, Amberlyn M. Wands, et al. · PLoS Pathogens · 76
PDF
Immune dysfunction in Niemann‐Pick disease type C
2015 · Nick Platt, Annelise O. Speak, et al. · Journal of Neurochemistry · 73
PDF
The use of fluorescence microscopy to define polymer localisation to the late endocytic compartments in cells that are targets for drug delivery
2008 · Simon C.W. Richardson, Kerri-Lee Wallom, et al. · Journal of Controlled Release · 57
Glycosphingolipid metabolism and its role in ageing and Parkinson’s disease
2021 · Kerri-Lee Wallom, María E. Fernández-Suárez, et al. · Glycoconjugate Journal · 44
PDF
Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes
2019 · Giulia Massaro, Michael P Hughes, et al. · Human Molecular Genetics · 39
PDF
Impact of polymer tacticity on the physico-chemical behaviour of polymers proposed as therapeutics
2011 · Lorella Izzo, Peter C. Griffiths, et al. · International Journal of Pharmaceutics · 27
Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels
2022 · Danielle te Vruchte, Andrea Sturchio, et al. · Movement Disorders · 23
PDF
Transcriptome of HPβCD-treated Niemann-Pick disease type C1 cells highlights GPNMB as a biomarker for therapeutics
2021 · Jorge L Rodriguez-Gil, Laura L Baxter, et al. · Human Molecular Genetics · 22
PDF
Cholera intoxication of human enteroids reveals interplay between decoy and functional glycoconjugate ligands
2023 · Akshi Singla, Andrew Boucher, et al. · Glycobiology · 11
PDF
Measuring relative lysosomal volume for monitoring lysosomal storage diseases
2015 · Danielle te Vruchte, Kerri L. Wallom, et al. · Methods in cell biology · 6
Glycoprotein non-metastatic melanoma protein B is a biomarker of inflammation in individuals with Gaucher disease: relationship to clinico-pathological subtypes
2025 · Sebile Kilavuz, Kerri-Lee Wallom, et al. · Orphanet Journal of Rare Diseases · 3
PDF
Dysregulation of the NLRP3 Inflammasome and Promotion of Disease by IL-1β in a Murine Model of Sandhoff Disease
2025 · Nick Platt, Dawn Shepherd, et al. · Cells · 3
PDF
Analysis of glycosphingolipids from human plasma v1
2021 · David A Priestman, Danielle te Vruchte, et al. · 3
Analysis of sphingosine, sphinganine and glucosylsphingosine from cells, animal tissues and plasma v1
2025 · Danielle te Vruchte, Yuzhe Weng, et al. · 2
PDF
Analysis of glycosphingolipids from human cerebrospinal fluid v1
2022 · David A Priestman, Reuben Bush, et al. · 2
PDF
Heat shock protein-based therapy for sphingolipidoses
2017 · Thomas Kirkegaard, James Gray, et al. · Molecular Genetics and Metabolism · 1
Correction: Miglustat as a Treatment for Adults with Tangier Disease Neuropathy: The MUSTANG N‑of‑1 Trial with 21 months Clinical Observation
2026 · Andrew Cook, Beth Stuart, et al. · Neurology and Therapy
PDF
Correction: Glycoprotein non-metastatic melanoma protein B is a biomarker of inflammation in individuals with Gaucher disease: relationship to clinico-pathological subtypes
2025 · Sebile Kilavuz, Kerri-Lee Wallom, et al. · Orphanet Journal of Rare Diseases
PDF
Miglustat as a Treatment for Adults with Tangier Disease Neuropathy: The MUSTANG N-of-1 Trial with 21 months Clinical Observation
2025 · Andrew Cook, Beth Stuart, et al. · Neurology and Therapy
PDF
Analysis of glucosylceramide from plasma and cerebrospinal fluid v2
2024 · David A Priestman, Danielle te Vruchte, et al.
PDF
Investigating the role of miglustat in the management of a patient with Tangier disease: An n-of-1 study with alternating periods of intervention and control
2024 · Tarekegn Geberhiwot, Antonio Ochoa-Ferraro, et al. · Molecular Genetics and Metabolism
Works count: 27
Citation count: 872
H-index: 12
I10-index: 13
Year
Topic
Type